N/A N=312 Pertussis Infection in Adolescents and Adults With Prolonged Cough
Pertussis
Primary: Serological Evidence of Pertussis Infection — 50; 74; 84; 26 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 Pertussis Challenge Study in Adults Vaccinated With BPZE1
Pertussis/Whooping Cough · Bordetella Pertussis, Whooping Cough
Primary: Number of Participants Colonized Following Virulent Challenge — 8; 12 Participants
N/A N=86 Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
Pertussis
Primary: Evidence of Pertussis Infection in Each PEP Arm, Defined Using Clinical, Microbiologic, or Serologic Criteria. — 6; 1 participants
N/A N=3,830 Seroepidemiological Study of Pertussis and Other Infectious Diseases
Pertussis Infection
Primary: IgG — 1.254; 1.258 EU/mL(log transformed)
Early Phase 1 N=42 Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women
Pertussis · Pregnancy Related
Primary: The Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG) in Pregnant Thai Women — 43 Participants
N/A N=290 Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States
Whooping Cough
Primary: Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During Third Trimester of Pregnancy) or Not Exposed to Any…
Phase 1 N=54 Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
Pertussis · Whooping Cough
Primary: The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events…
Phase 2 N=366 Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
Bordetella Pertussis, Whooping Cough
Primary: Geometric Mean Fold Rise (GMFR) of Mucosal Immunogenicity S-IgA Against Whole Cell Extract at Day 29 — 3.8; 3.5; 1.2 Fold Rise
Phase 4 N=215 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Pertussis · Diphtheria · Tetanus
Primary: Number of Participants Reporting a Solicited Local or Systemic Reaction Post-Vaccination With Either REPEVAX® or COVAXIS® Vaccine — 89; 87; 85; 87 Participants
N/A N=12,760 Increasing Influenza and Tdap Vaccination of Pregnant Women
Immunization; Infection · Pregnancy Related
Primary: Rate of Influenza Vaccination — 2382; 2496 participants
N/A N=2,000 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary
Pertussis · Pertussis Vaccines
Primary: Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations — 295 Participants
Phase 4 N=321 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Healthy Subjects
Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series — 100.0…
Phase 3 N=1,042 Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at ≥ 0.1 IU/mL Level — 65; 69; 100; 100…
Phase 1 N=420 Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
Pertussis · Whooping Cough · Tetanus
Primary: The Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine — 30; 33; 32; 35…
Phase 2 N=300 Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults
Pertussis · Whooping Cough
Primary: Number of Participants With Nasal Mucosal Seroconversion (Immunoglobulin A [IgA]) — 79; 89; 38; 42 Participants
N/A N=265 Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections
Infection
Primary: Number of Cough Bouts Over 4-hour Postdose Period — 139.6; 131.3; 126.4 Cough bouts — p=0.216
Phase 4 N=1,561 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
Pertussis · Tetanus · Diphtheria
Primary: Geometric Mean Titers (GMTs) of Tetanus, Diphtheria, and Pertussis Antibodies Pre- and Post-Vaccination With ADACEL® or DECAVAC® Vaccine — 0.501; 0.451; 8.43; 7.23 Titers
Phase 4 N=1,341 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 427; 405; 425; 412 Participants
Phase 3 N=754 Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
Hepatitis B · Pertussis
Primary: Percentage of Participants Responding to Hepatitis B Surface Antigen (HBsAg) — 70.16; 82.01; 65.75; 83.68 Percentage of Participants
Phase 3 N=447 Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects
Diphtheria-Tetanus-acellular Pertussis Vaccines
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D). — 437; 1 Participants
Phase 3 N=112 Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants With Antibody (Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids) Responses Pre- and Post-vaccination — 95; 99; 55; 99 Percentage of…
Phase 2 N=44 Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease
Cough · Parkinson's Disease
Primary: Peak Expiratory Flow Rate — 4.34; 3.92 Liters of air/second
Phase 4 N=55 Tdap Vaccine in Post-Partum Women
Diphtheria · Pertussis · Tetanus
Primary: Geometric Mean Fold Rise in Serum Immunoglobulin G (IgG) by ELISA at Week 2 — 4.8; 8.6; 21.6; 22.4 Fold Rise
Phase 4 N=211 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
Acellular Pertussis · Poliomyelitis · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens — 61; 66; 68; 63 Subjects
Phase 4 N=1,302 Study of Adacel® Vaccine Administered to Persons 10 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine — 30.1; 32.0; 232; 225 Titers (1/dilutions)
Phase 3 N=168 Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Assay Against N. Meningitidis Serogroups A, C Using Rabbit Complement (rSBA-MenA,C) Antibodies — 65; 59; 30; 66 Subjects
Phase 1 N=315 Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
Pertussis
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens at Day 1. — 28; 31; 48; 18 IU/mL
Phase 3 N=181 Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Phase 3 N=551 Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
Healthy Subjects
Primary: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter…
Phase 2 N=509 A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women
Respiratory Syncytial Virus Infections
Primary: Percentage of Subjects With Any Solicited Local Adverse Event (AEs) [Primary Study] — 5.9; 5; 5.8; 5.9 Percentage of participants